High Growth Tech Stocks Including Bonree Data Technology And 2 Others
In recent weeks, global markets have experienced volatility due to geopolitical tensions and concerns over consumer spending, with key indices like the S&P 500 showing fluctuations amid tariff fears and economic data releases. As investors navigate these uncertain times, identifying high-growth tech stocks can be crucial; companies that demonstrate strong innovation potential and adaptability may offer opportunities for growth even in challenging market conditions.
Name
Revenue Growth
Earnings Growth
Growth Rating
CD Projekt
27.11%
39.37%
★★★★★★
Ascelia Pharma
46.09%
66.93%
★★★★★★
Travere Therapeutics
28.04%
65.55%
★★★★★★
Pharma Mar
23.77%
45.40%
★★★★★★
Alkami Technology
21.99%
102.65%
★★★★★★
AVITA Medical
27.78%
55.33%
★★★★★★
TG Therapeutics
29.48%
45.20%
★★★★★★
Elliptic Laboratories
61.01%
121.13%
★★★★★★
Alnylam Pharmaceuticals
22.67%
58.73%
★★★★★★
Initiator Pharma
73.95%
31.67%
★★★★★★
Click here to see the full list of 1193 stocks from our High Growth Tech and AI Stocks screener.
Here we highlight a subset of our preferred stocks from the screener.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Bonree Data Technology Co., Ltd offers application performance management services for enterprises in China, with a market cap of CN¥2.69 billion.
Operations: Bonree Data Technology Co., Ltd specializes in application performance management services targeting enterprises within China. The company's revenue streams are primarily derived from providing these specialized services, reflecting its focus on enhancing enterprise software performance.
Bonree Data Technology, amid a volatile market, showcases promising growth with an expected revenue increase of 25.5% annually, outpacing the CN market's 13.4%. Despite current unprofitability, forecasts suggest a robust profit surge at an annual rate of 88%, positioning the firm for potential profitability within three years. This growth trajectory is supported by significant R&D investments that fuel innovation and competitiveness in the tech sector. As industries increasingly rely on data analytics and cloud services, Bonree's focus on these areas could substantially benefit its future market standing.
Take a closer look at Bonree Data Technology's potential here in our health report.
Assess Bonree Data Technology's past performance with our detailed historical performance reports.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Bona Film Group Co., Ltd. is involved in film production and distribution in China, with a market capitalization of CN¥6.88 billion.
Operations: The company focuses on film production and distribution within China. It operates with a market capitalization of CN¥6.88 billion, positioning itself as a significant player in the Chinese entertainment industry.
Bona Film Group, amidst a dynamic entertainment landscape, is poised for substantial growth with its revenue forecast to surge by 42.9% annually, significantly outstripping the industry norm. This impressive expansion is underpinned by an anticipated earnings growth of 117.4% per year, reflecting robust market demand and operational efficiency. The company's commitment to innovation is evident in its R&D investments, which are crucial for maintaining competitive edge and fueling future developments in a sector increasingly driven by digital consumption trends.
Delve into the full analysis health report here for a deeper understanding of Bona Film Group.
Learn about Bona Film Group's historical performance.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Shenzhen Sinovatio Technology Co., Ltd. specializes in network visualization, data and network security, and big data analysis, with a market cap of CN¥4.89 billion.
Operations: Sinovatio Technology focuses on providing solutions in network visualization, data security, and big data analysis. The company operates with a market cap of CN¥4.89 billion, reflecting its significant presence in the tech industry.
Shenzhen Sinovatio Technology is navigating a challenging yet promising trajectory in the tech sector. Despite being dropped from the S&P Global BMI Index recently, its revenue growth outlook remains robust at 23.9% annually, outpacing the Chinese market's average of 13.4%. This growth is supported by an expected surge in earnings by approximately 104.6% per year over the next three years as it transitions towards profitability. The company's strategic focus on R&D, crucial for maintaining competitiveness and fostering innovation in its offerings, underscores its potential to capitalize on emerging tech trends despite current unprofitability.
Get an in-depth perspective on Shenzhen Sinovatio Technology's performance by reading our health report here.
Gain insights into Shenzhen Sinovatio Technology's historical performance by reviewing our past performance report.
Embark on your investment journey to our 1193 High Growth Tech and AI Stocks selection here.
Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SHSE:688229 SZSE:001330 and SZSE:002912.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease
Seongnam-si, South Korea and Abu Dhabi, UAE, June 09, 2025 (GLOBE NEWSWIRE) -- AriBio Co., Ltd. ("AriBio"), a South Korean biopharmaceutical company specializing in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi (collectively 'Arcera'), today announced the signing of exclusive licensing and commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer's disease. Under the terms of the agreements, Arcera will have exclusive rights to commercialize AR1001 in its key markets, including Latin America, the Middle East, Southern Africa, Ukraine and select Eurasian countries. AriBio will be responsible for manufacturing and supplying the product. The total deal value is estimated at USD 600 million across the development, launch and commercialization period, contingent upon the achievement of certain milestones. AR1001 is a novel, disease-modifying, once-daily oral phosphodiesterase-5 (PDE5) inhibitor currently being studied in a global Phase 3 clinical trial (POLARIS-AD) for the treatment of early-stage Alzheimer's disease. The enrollment target for the Phase 3 trial has been reached, and the topline results are expected in the first half of 2026. Facilitated by the Korea Development Bank (KDB) and aligned with the Korean government's policy to foster the biohealth industry, this collaboration represents a significant step forward to enhance the global competitiveness of Korea's pharmaceutical and biotech industry. "This partnership with Arcera marks a significant milestone in our mission to bring innovative treatments to patients worldwide," said Jai Jun Choung, CEO of AriBio. "Arcera's strong commercial capabilities and deep understanding of the high-growth markets make them an ideal partner to advance AR1001 in these important regions." "We are excited to enter into this collaboration with AriBio, which will provide access to AR1001, a novel treatment, for patients across these countries," said Isabel Afonso, CEO of Arcera. "This agreement aligns with our strategy to expand our neuroscience portfolio and reinforces our commitment to providing access to novel therapies in regions with significant unmet medical needs." The agreement underscores both companies' dedication to addressing unmet medical needs in neurodegenerative diseases and enhancing patient access to innovative therapies globally. This deal follows the Memorandum of Understanding signed between AriBio and Arcera in March 2025, where both parties agreed to strengthen their partnership by actively exploring strategic investments, and advancing joint research and development based on shared interests. ENDS About AriBio Co., Ltd. Founded in 2010, AriBio is a clinical-stage biopharmaceutical company headquartered in South Korea, with offices located in the United States to manage global clinical operations and regulatory affairs. The company focuses on the development of novel therapies for neurodegenerative diseases, including Alzheimer's disease. AriBio continues to expand its partnerships to accelerate the development and delivery of life-changing treatments to patients worldwide. About Arcera Arcera is a global life sciences company, headquartered in Abu Dhabi. Arcera develops, manufactures, and commercializes a broad range of high-quality proven and innovative medicines in key international markets. Its portfolio exceeds 2,000 medicines covering wide therapeutic areas which reach patients in ninety countries in four continents, backed by manufacturing and packing sites across the world. Arcera was established by the sovereign wealth fund, ADQ to realize Abu Dhabi's ambition as a global leader in innovative and sustainable healthcare. To learn more about Arcera, visit Attachment AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease CONTACT: Tanya Xi, MD, PhD, MBA, Senior Director, Business Development & Medical Affairs, AriBio (US) AriBio Co., Ltd. tanyaxi@ Rafael Ferrer, SVP Corporate Development. Arcera rferrer@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
Undiscovered Gems in Middle East 3 Promising Stocks with Strong Potential
As the Middle East markets experience a positive momentum with UAE shares rising and Dubai's benchmark index reaching its highest levels since 2008, investors are keenly watching the outcome of U.S.-China trade talks for potential impacts on global economic prospects. In this dynamic environment, identifying promising stocks often involves looking at companies with strong fundamentals and growth potential that can thrive amidst evolving market conditions. Name Debt To Equity Revenue Growth Earnings Growth Health Rating Alf Meem Yaa for Medical Supplies and Equipment NA 17.03% 18.37% ★★★★★★ MOBI Industry 6.50% 5.60% 24.00% ★★★★★★ Baazeem Trading 8.48% -2.02% -2.70% ★★★★★★ Nofoth Food Products NA 14.41% 31.88% ★★★★★★ Sure Global Tech NA 11.95% 18.65% ★★★★★★ Saudi Azm for Communication and Information Technology 2.07% 16.18% 21.11% ★★★★★★ Alfa Solar Enerji Sanayi ve Ticaret 38.29% -32.50% -4.61% ★★★★★☆ Waja 23.81% 98.44% 14.54% ★★★★☆☆ Saudi Chemical Holding 79.49% 16.57% 44.01% ★★★★☆☆ Izmir Firça Sanayi ve Ticaret Anonim Sirketi 43.01% 40.80% -34.83% ★★★★☆☆ Click here to see the full list of 223 stocks from our Middle Eastern Undiscovered Gems With Strong Fundamentals screener. We're going to check out a few of the best picks from our screener tool. Simply Wall St Value Rating: ★★★★☆☆ Overview: Gulermak Aglr Sanayi Insaat ve Taahhut A.S. operates in the construction and engineering industry, with a market cap of TRY43.71 billion. Operations: GLRMK generates revenue primarily from three geographical segments: East (TRY6.30 billion), West (TRY24.48 billion), and Turkey (TRY8.38 billion). The company experiences a deduction in total revenue due to eliminations amounting to TRY7.81 billion, impacting its overall financial performance. Gulermak Aglr Sanayi Insaat ve Taahhut, a notable player in the Middle East construction sector, has demonstrated robust earnings growth of 23.7% over the past year, outpacing the industry average of 16.1%. Despite a dip in Q1 2025 sales to TRY 6,835.73 million from TRY 10,004.92 million last year and net income falling to TRY 1,162.15 million from TRY 1,789.25 million, its annual performance remains strong with FY2024 sales at TRY 34.51 billion and net income at TRY 3.57 billion compared to previous figures of TRY 26.46 billion and TRY 1.64 billion respectively; this showcases its resilience amidst challenges. Take a closer look at Gulermak Aglr Sanayi Insaat ve Taahhut's potential here in our health report. Learn about Gulermak Aglr Sanayi Insaat ve Taahhut's historical performance. Simply Wall St Value Rating: ★★★★★★ Overview: Ray Sigorta Anonim Sirketi operates in the non-life insurance sector in Turkey with a market capitalization of TRY38.32 billion. Operations: Ray Sigorta Anonim Sirketi generates revenue primarily from accident insurance, contributing TRY10.46 billion, followed by fire insurance at TRY1.42 billion. The company's financial performance can be analyzed through its net profit margin trends over time. Ray Sigorta, a nimble player in the insurance sector, has seen its earnings grow 70.8% annually over the past five years, yet recent figures show a net income of TRY 812.65 million for Q1 2025, down from TRY 924.17 million last year. Despite this dip and lower profit margins at 12.8% compared to last year's 28.3%, the company remains debt-free and boasts high-quality earnings with positive free cash flow indicators. The company's basic earnings per share also slipped to TRY 5 from TRY 6 year-on-year, indicating some challenges amid robust industry growth rates of over double its own recent performance increase of 23.3%. Click here and access our complete health analysis report to understand the dynamics of Ray Sigorta Anonim Sirketi. Explore historical data to track Ray Sigorta Anonim Sirketi's performance over time in our Past section. Simply Wall St Value Rating: ★★★★☆☆ Overview: Kenon Holdings Ltd. is a company that owns, develops, and operates power generation facilities in Israel and the United States, with a market capitalization of ₪6.79 billion. Operations: Kenon Holdings generates revenue primarily through its subsidiaries, with OPC Israel contributing $625.96 million and CPV Group adding $134.35 million. Kenon Holdings, a nimble player in the Middle East market, has seen its debt to equity ratio improve significantly from 93% to 46.9% over five years, indicating stronger financial health. Despite becoming profitable recently with net income of US$12 million for Q1 2025 compared to US$8 million a year ago, its interest coverage remains tight at just 1.1x EBIT. The company's shares are trading at a substantial discount of 63.4% below estimated fair value and it recently completed share buybacks totaling US$48 million, reflecting confidence in its future prospects despite challenges with free cash flow positivity. Delve into the full analysis health report here for a deeper understanding of Kenon Holdings. Examine Kenon Holdings' past performance report to understand how it has performed in the past. Take a closer look at our Middle Eastern Undiscovered Gems With Strong Fundamentals list of 223 companies by clicking here. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include IBSE:GLRMK IBSE:RAYSG and TASE:KEN. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
San Francisco Chronicle
27 minutes ago
- San Francisco Chronicle
Asian shares gain as investors keep an eye on China-US trade talks
Asian shares were mostly higher on Tuesday as investors kept an eye on China-U.S. trade talks that might help stave off a recession. A second day of talks was planned after U.S. and Chinese officials met in London for negotiations over various issues. The hope is that they can eventually reach a deal to reduce painfully high tariffs against each other. Most of the tariff hikes imposed since U.S. President Donald Trump escalated his trade war are paused to allow trade in everything from tiny tech gadgets to enormous machinery to continue. In Asian trading, Tokyo's Nikkei 225 gained 1% to 38,473.97, while the Kospi in South Korea jumped 0.9% to 2,881.40. Hong Kong's Hang Seng edged 0.2% higher, to 24,242.03 and the Shanghai Composite index was up 0.1% at 3,403.51. In Taiwan, the Taiex surged 2%. Australia's S&P/ASX 200 advanced 0.7% to 8,578.50. On Monday, the S&P 500 edged up just 0.1% and at 6,005.88 is within 2.3% of its record set in February. The Dow Jones Industrial Average slipped by 1 point, which is well below 0.1%, to 42,761.76. The Nasdaq composite added 0.3% to 19,591.24. Hopes that President Donald Trump will lower his tariffs after reaching trade deals with countries around the world have helped the S&P 500 has rally back after it dropped roughly 20% from its record two months ago. It's back above where it was when Trump shocked financial markets in April with his wide-ranging tariff announcement on what he called 'Liberation Day.' Some of the market's biggest moves came from the announcement of big buyout deals. Qualcomm rallied 4.1% after saying it agreed to buy Alphawave Semi in a deal valued at $2.4 billion. IonQ, meanwhile, rose 2.7% after the quantum computing and networking company said it agreed to purchase Oxford Ionics for nearly $1.08 billion. On the losing side of Wall Street was Warner Bros. Discovery, which flipped from a big early gain to a loss of 3% after saying it would split into two companies. One will get Warner Bros. Television, HBO Max and other studio brands, while the other will hold onto CNN, TNT Sports and other entertainment, sports and news television brands around the world, along with some digital products. Tesla recovered some of its sharp, recent drop. The electric vehicle company tumbled last week as Elon Musk's relationship with Trump broke apart, and it rose 4.6% Monday after flipping between gains and losses earlier in the day. The frayed relationship could end up damaging Musk's other companies that get contracts from the U.S. government, such as SpaceX. Rocket Lab, a space company that could pick up business at SpaceX's expense, rose 2.5%. In the bond market, the yield on the 10-year Treasury eased to 4.48% from 4.51% late Friday. It fell after a survey by the Federal Reserve Bank of New York found that consumers' expectations for coming inflation eased a bit in May. Economists expect a report coming on Wednesday to show inflation across the country accelerated last month to 2.5% from 2.3%. The Fed has been keeping its main interest rate steady as it waits to see how much Trump's tariffs will raise inflation and how much they will hurt the economy. A persistent increase in expectations for inflation among U.S. households could drive behavior that creates a vicious cycle that only worsens inflation. In other dealings early Tuesday, U.S. benchmark crude oil picked up 31 cents to $65.60 per barrel. Brent crude, the international standard, also gained 31 cents, to $67.35. The dollar rose to 144.93 Japanese yen from 144.61 yen. The euro slipped to $1.1399 from $1.1421. ___
